Beroni Group to Supply COVID-19 Antibody Test Kit to Japan


NEW YORK and SYDNEY, Australia, July 10, 2020 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni” or the “Company”), an international diversified biopharmaceutical enterprise focused on the research, development, innovation and commercialization of therapies and products for treatment of global diseases, is pleased to announce that it is collaborating with Forsitech Inc. (“Forsitech”) and Standard Capital Co., Ltd (“Standard Capital”) to supply its SARS-CoV-2 total antibody detection kit for clinical testing in the Japanese market. Beroni will start with a supply of 100,000 test kits to be distributed by these two Japanese partners.

The ALLEX platform, a digital STO (security token offerings) exchange solution developed by Standard Capital will be used to ensure smooth and fast delivery of the test kits to the Japanese market. It will also provide necessary and timely information updates, and the system will incorporate a service that recommends retesting 14 days after the initial testing. Given the current global pandemic situation, asymptomatic patients pose a significant risk of infection and should be tested early for presence of antibodies to prevent hidden cluster outbreaks. As asymptomatic patients are not given much opportunity to undergo antibody testing, ALLEX will support those who wish to be tested for antibodies to prevent the spread of infection.

Jacky Zhang, Chairman and CEO of Beroni Group, said, “We are very excited to be able to work with Forsitech and Standard Capital to provide antibody testing to the Japanese market on a broader scale. We believe that the antibody testing is an effective means to quickly detect the spread of the COVID-19 virus and prevent massive outbreaks.”

About Beroni Group Limited

Beroni Group is an international biopharmaceutical enterprise dedicated to the innovation and commercialization of drugs and therapies to combat various global diseases such as cancer and infectious diseases. Its diversified portfolio is comprised of a US FDA approved virus diagnostic kit, an e-commerce platform for the sale of pharmaceutical products and a development pipeline targeting oncology and cell therapies. Beroni has operations in Australia, United States, China and Japan. It is listed on the National Stock Exchange of Australia and traded on the OTC markets in the USA.

To learn more about Beroni, please visit

About FORSiTECH Inc.

Forsitech Inc. is a Tokyo-based pharmaceutical trading company dealing in bulk pharmaceuticals, pharmaceutical intermediates, cosmetics and other products. It provides a smooth supply chain for pharmaceuticals and other related products, leveraging its specialized knowledge of pharmaceuticals and its experience in the field of import and marketing approval. The company also assists pharmaceutical manufacturers with registration of their products with PMDA and protection of the intellectual property rights of their products and technology. In addition, Forsitech is currently donating PPE items such as surgical masks and protective clothings to medical institutions.

The CEO of Forsitech Inc. is Hajime Funaki. To find out more about Forsitech, please visit

About Standard Capital Co., Ltd

Standard Capital Co., Ltd has developed an identity authentication system and aims to expand the security business in relation to it. Its ALLEX ID, which can manage personal information with robust security, can be applied to many fields. The company is also working on the provision of security enhancement service for the electronic contracting business. It will promote the popularity and technological development of electronic contracting services, as well as providing an online donation system for supporting medical technology projects.

ALLEX is also an STO exchange that can be funded by securities issued using blockchain and other electronic means. It can be used to revitalize the financial and capital markets and improve the efficiency of the financial system.

Standard Capital provided continuous consulting services such as security token issuance, management, settlement, and incidental operations, as well as compliance with laws and regulations aimed at protecting investors.

Its CEO is Taisei Yamaguchi. To find out more Standard Capital, please visit

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements or forward-looking information, within the meaning of applicable United States and Australian securities laws with respect to the Company. By their nature, forward-looking statements are subject to a variety of factors that could cause actual results to differ materially from the results suggested by the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking statements. Generally forward-looking statements can be identified by the use of terminology such as “anticipate”, “will”, “expect”, “may”, “continue”, “could”, “estimate”, “forecast”, “plan”, “intend”, “believe”, “potential” and similar expressions.

Forward-looking information contained in this press release is based on Company management’s opinions, estimates and assumptions in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward-looking statements involve significant risks, uncertainties and assumptions, and there can be no assurance that such statements, or its underlying risks, uncertainties and assumptions will prove to be accurate.  Factors that could cause actual results or events to differ materially include, without limitation, risks related to laws, rules and regulation applicable to the Company as well as the industry in which it operates (including in respect of taxes and other levies), economic or market conditions on both a national and global level, currency fluctuations, risks inherent to other entities at a similar stage of development and industry in which the Company currently is, competition from the Company’s competitors, unsatisfactory development or marketing of the Company and/or its products or services, regulatory action or litigation (including product liability claims), and failure to enter into agreements or arrangements with other parties on fair or reasonable terms.  Forward-looking information is made only as of the date on which it is provided and, except as may be required by applicable laws, the Company disclaims any intent or obligation to update such forward-looking information whether as a result of new information, future events or otherwise.

For more information, please contact:

Phone: +61 2 8051 3055